Ceftazidime in neonatal infections

Insights

Ceftazidime showed high serum concentrations and good cerebrospinal fluid penetration in neonates. However, it was ineffective against Gram-positive organisms, limiting its use as monotherapy before culture results are known.

Area of Science:

  • Neonatal pharmacology
  • Infectious diseases
  • Antibiotic therapy

Background:

  • Neonatal infections require effective and safe antibiotic treatment.
  • Ceftazidime is a broad-spectrum cephalosporin with theoretical suitability for neonatal use.
  • Limited data exist on ceftazidime efficacy and safety in neonates.

Purpose of the Study:

  • To evaluate the efficacy and safety of intravenous ceftazidime in neonates with suspected or proven infections.
  • To assess ceftazidime serum concentrations, cerebrospinal fluid penetration, and clinical outcomes.

Main Methods:

  • A prospective study of 91 neonates receiving 108 courses of intravenous ceftazidime (25 mg/kg, 12-hourly).
  • Clinical and bacteriological data were collected for 14 neonates with proven infections.
  • Serum drug concentrations and cerebrospinal fluid penetration were monitored.

Main Results:

  • High serum ceftazidime concentrations were achieved, exceeding minimum inhibitory concentrations for common pathogens.
  • Excellent cerebrospinal fluid penetration was observed in 8 of 9 cases.
  • Four neonates with Gram-positive infections (Group B Streptococcus, Staphylococcus aureus) failed to respond.
  • Nine neonates showed clinical improvement or bacteriological eradication, with no observed side effects.

Conclusions:

  • Ceftazidime demonstrates favorable pharmacokinetic properties in neonates, including high serum levels and CSF penetration.
  • The antibiotic was effective against Gram-negative infections but ineffective against Gram-positive organisms in this study.
  • Ceftazidime cannot be recommended as monotherapy for neonatal infections until bacteriological culture results are available.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...